Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Injectable omeprazole ‘can be used within rules’, BHA confirms
"Long-acting injectable omeprazole has become an important treatment option for horses with gastric disease" - Dr Mike Hewetson. 

Vets had been previously advised against using the drug owing to traces of testosterone

The British Horseracing Authority (BHA) has announced that injectable omeprazole, manufactured by Bova UK, can now be used in racehorses ‘within rules’.

Veterinary professionals had previously been advised against possessing, using or administering the drug in racehorses after small traces of testosterone were discovered in a batch of the product last year.


Although independent experts said there could be no adverse effects on equine health or equestrian sport, BOVA took immediate action to identify and eliminate the ingredient that contained the testosterone.


In September 2019, the product was declared free of testosterone and has since continued to be used in Australian racehorses after guidance from Racing NSW. Tests on multiple samples of injectable omeprazole ahead of sale have also since demonstrated the product to be free of testosterone. 


Dr Mike Hewetson from the Royal Veterinary College explained: “Long-acting injectable omeprazole has become an important treatment option for horses with gastric disease, particularly those affected by glandular gastric disease.”

A recent blind clinical trial of Bova’s injectable omeprazole found that healing rates for both glandular and squamous gastric disease were four times higher with injectable omeprazole than with a registered oral product.

Become a member or log in to add this story to your CPD history

FIVP publishes CMA Compliance Checklist

News Story 1
 FIVP has published a CMA Compliance Checklist to support independent practices with the Market Investigation Order.

The document includes deadlines for small and large businesses, with tick boxes for each of the tasks. The organisation also invites practices to contact them for support with requirements.

Rita Dingwall, FIVP chair, said: FIVP appreciates that navigating the new CMA requirements can feel daunting. We hope this checklist will make things a little easier, helping independent practices work through what is required with confidence. 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.